64 results
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals, Inc.
18 Jun 24
Entry into a Material Definitive Agreement
8:36am
to open U.S. and ex-U.S. clinical sties. 24 3 DAY101 + Pimasertib until disease progression, intolerable toxicity, withdrawal of consent, or death
DAY301
8-K
EX-99.1
DAWN
Day One Biopharmaceuticals, Inc.
12 Jun 24
Regulation FD Disclosure
8:07am
. clinical sties. 24 3 DAY101 + Pimasertib until disease progression, intolerable toxicity, withdrawal of consent, or death
Summary 25
Financial Summary
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals, Inc.
30 May 24
Day One Announces Sale of Priority Review Voucher for $108 Million
8:35am
sties. 24 3 DAY101 + Pimasertib until disease progression, intolerable toxicity, withdrawal of consent, or death
Summary 25
Financial Summary: DAWN
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals, Inc.
6 May 24
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
4:30pm
of consent, or death Endpoints Combination dose escalation, global phase 1b/2 trial2 Phase 1b, BOIN (adaptive), n = 10/cohort (approximately) Phase 2, Simon 2
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals, Inc.
24 Apr 24
Regulation FD Disclosure
8:01am
sties. 24 3 DAY101 + Pimasertib until disease progression, intolerable toxicity, withdrawal of consent, or death
Summary 25
Financial Summary: DAWN
8-K
EX-99.2
60sjad8g9
26 Feb 24
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.2
02s5qcpk
8 Jan 24
Regulation FD Disclosure
8:30am
S-8
EX-99.2
sfr 9li4zglhg5wqq
4 Jan 24
Registration of securities for employees
4:06pm
S-8
EX-99.1
wx8yn
4 Jan 24
Registration of securities for employees
4:06pm
8-K
EX-99.2
dsl5o
17 Nov 23
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
7:07am
8-K
EX-99.2
2ail5jn1
6 Nov 23
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.2
niiqpzk
30 Oct 23
Regulation FD Disclosure
8:12am
8-K
EX-99.2
bsfx9oljg5b8i6
11 Sep 23
Regulation FD Disclosure
8:35am
8-K
EX-99.2
ukjex4xlj vi0r3d
16 Aug 23
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
8:06am
8-K
EX-99.2
oc1akhw 5e
7 Aug 23
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.1
3d3 gvahpnvxa64
12 Jun 23
Regulation FD Disclosure
8:07am
8-K
EX-1.1
ib1i 2yhpyjj47lw0s
7 Jun 23
Day One Announces Pricing of Public Offering of Common Stock
5:00pm